| Administration route |
intravenous infusion |
| Dosage |
2E6 cells/kg |
| Donor type |
Autologous |
| Pts |
68 |
| Age |
Adult, Older_Adult |
| Lymph depletion |
Yes |
| Outcome |
93%(CR) |
| Adverse reactions |
16/68(All-cause Mortality); 46/68(Blood and lymphatic system disorders; Cardiac disorders; Gastrointestinal disorders; General disorders; Infections and infestations; Injury, poisoning and procedural complications; Metabolism and nutrition disorders; Musculoskeletal and connective tissue disorders; Neoplasms benign, malignant and unspecified; Nervous system disorders; Psychiatric disorders; Renal and urinary disorders; Respiratory, thoracic and mediastinal disorders; Skin and subcutaneous tissue disorders; Vascular disorders) |
|